5.50
0.10 (1.85%)
| Previous Close | 5.40 |
| Volume | 4,687,675 |
| Price / Sales | 86.48 |
| Price / Book | 6.50 |
| 52 Weeks Range |
| Operating Margin (TTM) | -1,222.27% |
| Diluted EPS (TTM) | -1.59 |
| Quarterly Revenue Growth (YOY) | -39.30% |
| Total Debt/Equity (MRQ) | 1.72% |
| Current Ratio (MRQ) | 5.06 |
| Operating Cash Flow (TTM) | -12.32 M |
| Levered Free Cash Flow (TTM) | -52.41 M |
| Return on Assets (TTM) | -18.20% |
| Return on Equity (TTM) | -91.03% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Aclaris Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -2.50 |
|
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 2.69% |
| % Held by Institutions | 88.24% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |